200.15
+4.09%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Revolution Medicines
From its filings with the US Securities and Exchange Commission
Revolution Medicines is based in Redwood City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RVMD. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $1.13bn. At that date it held total assets of $2.35bn and shareholders' equity of $1.63bn.
We are a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. We possess sophisticated structure-based drug discovery capabilities built upon deep chemical biology and cancer pharmacology know-how and innovative, proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Guided by our understanding of genetic drivers and adaptive resistance mechanisms in cancer, we deploy precision medicine approaches to inform innovative monotherapy and combination regimens. Our research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors) that are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
We believe tailored RAS(ON) Inhibitors will be useful to serve the diverse landscape of RAS-addicted cancers optimally. In some cases, patients may experience maximal clinical benefit from the broad activity of a RAS(ON) multi-selective inhibitor, such as daraxonrasib (RMC-6236), which is designed to inhibit multiple oncogenic RAS variants. In other settings, treatment with a RAS(ON) mutant-selective inhibitor, designed to selectively target a specific RAS mutation, may be optimal. We further believe that in some cases, it could be beneficial to combine daraxonrasib with a RAS(ON) mutant-selective inhibitor, with daraxonrasib functioning as the backbone of these RAS(ON) Inhibitor doublets.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 13 Feb 2020
- Employees
- 883
- Website
- revolutionmedicines.com ↗
- Head office
- 700 SAGINAW DR, REDWOOD CITY, CA, 94063
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Dr. Mark GoldsmithChairman of the Board, President, Chief Executive Officer, since 2014$10.1m
- Mr. Jack AndersChief Financial Officer, since 2022$3.3m
- Dr. Steve KelseyPresident - Research and Development$5.9m
- Ms. Margaret HornChief Operating Officer$4.9m
- Ms. Xiaolin WangExecutive Vice President - Development$3.1m
- Mr. Jeff CisliniSenior Vice President, General Counsel, Secretary
- Dr. Wei LinChief Medical Officer
- Dr. Alan SandlerChief Development Officer
- Mr. Alexis BorisyLead Independent Director$618,374
- Ms. Elizabeth AndersonIndependent Director$593,124
- Dr. Flavia BorelliniIndependent Director$598,525
- Mr. Franklin ClyburnIndependent Director$1.0m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 49
- Environment
- 54
- Social
- 42
- Governance
- 50
- Women in the workforce
- 56%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Revolutionary approach to medicine development and treatment.
- Strong research and development capabilities.
- Well-established partnerships with leading pharmaceutical companies.
- Skilled and experienced team of scientists and professionals.
- Excellent track record in achieving milestones and advancing pipeline.
Weaknesses
- Relatively small market presence compared to established pharmaceutical companies.
- Limited financial resources may restrict expansion and research endeavors.
- High reliance on successful clinical trials for product approval and commercialization.
- Vulnerability to regulatory changes and compliance requirements.
- Potential difficulty in attracting and retaining top talent in a competitive industry.
Opportunities
- Growing demand for targeted therapies and precision medicines.
- Increasing investments in healthcare and life sciences.
- Potential collaborations with academic institutions for research partnerships.
- Expansion into new geographic markets to reach a wider patient population.
- Emerging technologies like Artificial Intelligence for drug discovery.
Threats
- Intense competition from large pharmaceutical companies.
- Price pressures and reimbursement challenges in the healthcare industry.
- Delays or failures in clinical trials leading to setbacks in product development.
- Stringent regulatory requirements and potential delays in obtaining approvals.
- Intellectual property infringement and legal disputes.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.